Replimune Group Inc (NASDAQ: REPL) on Friday, soared 35.11% from the previous trading day, before settling in for the closing price of $11.05. Within the past 52 weeks, REPL’s price has moved between $4.92 and $12.97.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 9.80%. With a float of $54.44 million, this company’s outstanding shares have now reached $61.42 million.
In an organization with 331 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 48.27%, operating margin of -5729.32%, and the pretax margin is -5260.12%.
Replimune Group Inc (REPL) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Replimune Group Inc is 20.30%, while institutional ownership is 89.48%. The most recent insider transaction that took place on Nov 18 ’24, was worth 78,112. In this transaction Chief Medical Officer of this company sold 7,246 shares at a rate of $10.78, taking the stock ownership to the 109,885 shares. Before that another transaction happened on Nov 18 ’24, when Company’s Chief Commercial Officer sold 5,207 for $10.78, making the entire transaction worth $56,131. This insider now owns 87,045 shares in total.
Replimune Group Inc (REPL) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 9.80% per share during the next fiscal year.
Replimune Group Inc (NASDAQ: REPL) Trading Performance Indicators
Replimune Group Inc (REPL) is currently performing well based on its current performance indicators. A quick ratio of 10.11 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.12, a number that is poised to hit -0.76 in the next quarter and is forecasted to reach -2.67 in one year’s time.
Technical Analysis of Replimune Group Inc (REPL)
Let’s dig in a bit further. During the last 5-days, its volume was 1.95 million. That was better than the volume of 1.05 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 38.44%. Additionally, its Average True Range was 1.01.
During the past 100 days, Replimune Group Inc’s (REPL) raw stochastic average was set at 77.35%, which indicates a significant increase from 67.81% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 133.32% in the past 14 days, which was higher than the 72.58% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $11.59, while its 200-day Moving Average is $9.15. However, in the short run, Replimune Group Inc’s stock first resistance to watch stands at $16.91. Second resistance stands at $18.89. The third major resistance level sits at $20.78. If the price goes on to break the first support level at $13.04, it is likely to go to the next support level at $11.15. Assuming the price breaks the second support level, the third support level stands at $9.17.
Replimune Group Inc (NASDAQ: REPL) Key Stats
Market capitalization of the company is 1.38 billion based on 68,417K outstanding shares. Right now, sales total 0 K and income totals -215,790 K. The company made 0 K in profit during its latest quarter, and -53,060 K in sales during its previous quarter.
